Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
about
Kallikreins as biomarkers for prostate cancerProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesMultiple newly identified loci associated with prostate cancer susceptibilityThe relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group[Rates of prostate-specific antigen testing for early detection of prostate cancer: a first comparison of German results with current international data].Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyMultivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostatesMen (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohortFinasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohortProstate cancer: estimating the benefits of PSA screeningEthnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting.Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.Sample size estimation for time-dependent receiver operating characteristic.The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.Prostate specific antigen testing among the elderly--when to stop?Serum markers in prostate cancer detectionEmpirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.CD117⁺ cells in the circulation are predictive of advanced prostate cancerProstate kallikrein markers in diagnosis, risk stratification and prognosis.Recent Advances on Luminescent Enhancement-Based Porous Silicon Biosensors.Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesTumor markers in prostate cancer I: blood-based markers.Blood biomarkers for prostate cancer detection and prognosis.New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.Systematic review of statistical methods used in molecular marker studies in cancer.Screening for prostate cancer: an update.Prostate specific antigen for early detection of prostate cancer: longitudinal study.Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancerSNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?
P2860
Q26862434-9D0F049D-7EFF-4EBA-A18F-213D88FE4A88Q26865810-774EC95E-BB56-48B0-9B80-B96ECA70F6BEQ28268180-547297E6-C2AC-4875-984F-18C655AE7298Q28749313-F2B33AF7-6554-435C-9B79-0BF5662CA119Q30793372-E6614041-7202-4D0F-9DCD-CC2F06248B6AQ31044291-9C72998D-591A-4667-91BC-5BFE1DB3C97DQ31161981-91182E93-1A6C-449E-8EFB-BAF548D69CD2Q33320071-2A4EFCCB-AAFE-4332-83AE-E0A2C6447771Q33389634-374C3661-2506-4D39-83CE-51560EC80AA9Q33643656-436699A9-1832-407B-94B3-C9885E0D8548Q33710942-1B0F1338-95EA-4492-AFEC-59B7432A45E4Q33820579-B4A250D3-D8B7-4D7F-B734-4537F4FEAEEFQ33823085-D0E7F2ED-E63B-4B6C-B483-D9666909CDB0Q34027912-8E483BBA-800C-44CB-8B0A-813E6C02A5F9Q34084330-08EB4B34-077C-4C12-B852-3756B80D8D5BQ34130128-69817ABB-0E32-4811-939A-AFD766C3DD5EQ34222867-10B70AC8-6F35-42DF-8DD2-1F32E50933C8Q34512629-C9680D8B-B30D-4DAC-A008-4794841BCE24Q34561148-A311122F-C41E-4E96-AD1D-F8C20BBDDE82Q34604893-C16E3224-D3B8-46EE-B18F-FE5EDAF6DF32Q35042519-A35BCD86-54C5-4C58-8BB4-F1607D348075Q35089983-50153E72-C3EC-4621-96A7-F5EEA9A5E212Q35176469-154D4171-DABE-415B-8CFE-202D0B642C1EQ35683035-9347B047-1D01-40AC-99C3-E1E0C8B98B60Q35936196-B969FFC2-C053-4D3B-8D2A-4525D3E547EAQ35947528-5180D4EC-2B16-4982-8200-F4DE3CC314FCQ36142693-3978020E-1C6D-448A-B21D-849E9D0F0F96Q36177334-D247434D-1F38-4997-9FE7-C69F0E00A951Q36326373-44DCA509-F056-4124-A1B6-515DAC5553EEQ36607766-284749FB-4587-4C5A-9489-494BA11FC4AEQ36895818-868DA1D1-849B-4EBD-9EC3-A00212749E74Q36973830-3EFF476D-1ABD-4334-8BC4-85F80EA3C8FBQ37001231-5EDFA364-6132-4CFF-84FE-CB54231AC6EEQ37043425-8BB1F3EA-5132-4715-A932-F898088B1476Q37102352-588449C4-0FCE-4FDE-A010-E7D008893F59Q37338478-4440B45A-201C-45E1-A17F-7E223C98B496Q37362535-E752EF73-6C67-4F8A-9D30-4B8B1C1235D4Q37419880-C9C23B7C-1D17-43ED-934D-F40928AFF87BQ37422990-D0999875-9291-45C2-8BF8-0CA86E0AA6C7Q37440810-CCAD1FB9-8EC8-4FE9-AB14-7D6BB506F5BB
P2860
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Long-term prediction of prosta ...... easured at age 44 to 50 years.
@en
type
label
Long-term prediction of prosta ...... easured at age 44 to 50 years.
@en
prefLabel
Long-term prediction of prosta ...... easured at age 44 to 50 years.
@en
P2093
P50
P356
P1476
Long-term prediction of prosta ...... measured at age 44 to 50 years
@en
P2093
Angel M Serio
Charlotte Becker
Göran Berglund
Jan-Ake Nilsson
Per-Anders Abrahamsson
Thomas Björk
P304
P356
10.1200/JCO.2006.06.9351
P407
P577
2007-02-01T00:00:00Z